RU2012146518A - Антагонисты экспрессии мкрнк-29 и их применение в профилактике и лечении аневризмы аорты - Google Patents
Антагонисты экспрессии мкрнк-29 и их применение в профилактике и лечении аневризмы аорты Download PDFInfo
- Publication number
- RU2012146518A RU2012146518A RU2012146518/15A RU2012146518A RU2012146518A RU 2012146518 A RU2012146518 A RU 2012146518A RU 2012146518/15 A RU2012146518/15 A RU 2012146518/15A RU 2012146518 A RU2012146518 A RU 2012146518A RU 2012146518 A RU2012146518 A RU 2012146518A
- Authority
- RU
- Russia
- Prior art keywords
- μrna
- antagonist
- expression
- antisense
- activity
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title claims abstract 27
- 230000014509 gene expression Effects 0.000 title claims abstract 14
- 230000002265 prevention Effects 0.000 title claims abstract 3
- 208000007474 aortic aneurysm Diseases 0.000 claims abstract 12
- 230000000694 effects Effects 0.000 claims abstract 9
- 150000001875 compounds Chemical class 0.000 claims abstract 7
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims abstract 6
- 239000000074 antisense oligonucleotide Substances 0.000 claims abstract 6
- 238000012230 antisense oligonucleotides Methods 0.000 claims abstract 6
- 238000000034 method Methods 0.000 claims abstract 6
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract 5
- -1 for example Proteins 0.000 claims abstract 5
- 208000002223 abdominal aortic aneurysm Diseases 0.000 claims abstract 4
- 230000015572 biosynthetic process Effects 0.000 claims abstract 4
- 210000001519 tissue Anatomy 0.000 claims abstract 4
- 108020004491 Antisense DNA Proteins 0.000 claims abstract 3
- 108020005544 Antisense RNA Proteins 0.000 claims abstract 3
- 102000008186 Collagen Human genes 0.000 claims abstract 3
- 108010035532 Collagen Proteins 0.000 claims abstract 3
- 102100033601 Collagen alpha-1(I) chain Human genes 0.000 claims abstract 3
- 102100036213 Collagen alpha-2(I) chain Human genes 0.000 claims abstract 3
- 102100033167 Elastin Human genes 0.000 claims abstract 3
- 108010014258 Elastin Proteins 0.000 claims abstract 3
- 101000875067 Homo sapiens Collagen alpha-2(I) chain Proteins 0.000 claims abstract 3
- 108010016731 PPAR gamma Proteins 0.000 claims abstract 3
- 102000000536 PPAR gamma Human genes 0.000 claims abstract 3
- 108010029483 alpha 1 Chain Collagen Type I Proteins 0.000 claims abstract 3
- 230000000692 anti-sense effect Effects 0.000 claims abstract 3
- 239000003816 antisense DNA Substances 0.000 claims abstract 3
- 210000004027 cell Anatomy 0.000 claims abstract 3
- 229920001436 collagen Polymers 0.000 claims abstract 3
- 239000003184 complementary RNA Substances 0.000 claims abstract 3
- 108060002895 fibrillin Proteins 0.000 claims abstract 3
- 102000013370 fibrillin Human genes 0.000 claims abstract 3
- 239000000203 mixture Substances 0.000 claims abstract 3
- 108020004707 nucleic acids Proteins 0.000 claims abstract 3
- 102000039446 nucleic acids Human genes 0.000 claims abstract 3
- 150000007523 nucleic acids Chemical class 0.000 claims abstract 3
- 102000016942 Elastin Human genes 0.000 claims abstract 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims abstract 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims abstract 2
- 241000124008 Mammalia Species 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims abstract 2
- 229940079593 drug Drugs 0.000 claims abstract 2
- 229920002549 elastin Polymers 0.000 claims abstract 2
- 230000003313 weakening effect Effects 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 102100031509 Fibrillin-1 Human genes 0.000 claims 2
- 101000846893 Homo sapiens Fibrillin-1 Proteins 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- 238000011156 evaluation Methods 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 238000000636 Northern blotting Methods 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 210000000709 aorta Anatomy 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 238000003757 reverse transcription PCR Methods 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 206010060874 Aortic rupture Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10003675.5 | 2010-04-01 | ||
| EP10003675A EP2371370A1 (en) | 2010-04-01 | 2010-04-01 | Antagonists of miRNA-29 expression and their use in the prevention and treatment of aortic aneurysms and atherosclerotic plaque destabilization |
| PCT/EP2011/055122 WO2011121120A1 (en) | 2010-04-01 | 2011-04-01 | ANTAGONISTS OF miRNA-29 EXPRESSION AND THEIR USE IN THE PREVENTION AND TREATMENT OF AORTIC ANEURYSMS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012146518A true RU2012146518A (ru) | 2014-05-10 |
Family
ID=42269707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012146518/15A RU2012146518A (ru) | 2010-04-01 | 2011-04-01 | Антагонисты экспрессии мкрнк-29 и их применение в профилактике и лечении аневризмы аорты |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9062307B2 (enExample) |
| EP (2) | EP2371370A1 (enExample) |
| JP (2) | JP6224455B2 (enExample) |
| CN (1) | CN102939090A (enExample) |
| AU (1) | AU2011234453B2 (enExample) |
| CA (1) | CA2795164C (enExample) |
| ES (1) | ES2690198T3 (enExample) |
| RU (1) | RU2012146518A (enExample) |
| WO (1) | WO2011121120A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20030376A1 (it) | 2003-07-31 | 2005-02-01 | Univ Roma | Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia. |
| US11660317B2 (en) | 2004-11-08 | 2023-05-30 | The Johns Hopkins University | Compositions comprising cardiosphere-derived cells for use in cell therapy |
| US9845457B2 (en) | 2010-04-30 | 2017-12-19 | Cedars-Sinai Medical Center | Maintenance of genomic stability in cultured stem cells |
| US9249392B2 (en) | 2010-04-30 | 2016-02-02 | Cedars-Sinai Medical Center | Methods and compositions for maintaining genomic stability in cultured stem cells |
| US8618073B2 (en) | 2010-07-22 | 2013-12-31 | The University Of North Carolina At Chapel Hill | Use of miR-29 for cell protection |
| JP2015518475A (ja) * | 2012-04-10 | 2015-07-02 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラルシェルシェ メディカル）Ｉｎｓｅｒｍ（Ｉｎｓｔｉｔｕｔ Ｎａｔｉｏｎａｌ Ｄｅｌａ Ｓａｎｔｅ Ｅｔｄｅ Ｌａ Ｒｅｃｈｅｒｃｈｅ Ｍｅｄｉｃａｌｅ） | 非アルコール性脂肪性肝炎の治療方法 |
| EP2861238A4 (en) | 2012-06-05 | 2016-03-16 | Capricor Inc | OPTIMIZED METHODS FOR GENERATING CARDIAC STEM CELLS FROM CARDIAC TISSUE AND THEIR USE IN CARDIAC THERAPY |
| US9828603B2 (en) | 2012-08-13 | 2017-11-28 | Cedars Sinai Medical Center | Exosomes and micro-ribonucleic acids for tissue regeneration |
| RU2712511C2 (ru) * | 2014-09-08 | 2020-01-29 | Мираген Терапеутикс, Инк. | Миметики mir-29 и пути их применения |
| US11357799B2 (en) | 2014-10-03 | 2022-06-14 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy |
| EP3247716A4 (en) | 2015-01-20 | 2018-10-17 | Miragen Therapeutics, Inc. | Mir-92 inhibitors and uses thereof |
| EP3402543B1 (en) | 2016-01-11 | 2021-09-08 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction |
| US11351200B2 (en) | 2016-06-03 | 2022-06-07 | Cedars-Sinai Medical Center | CDC-derived exosomes for treatment of ventricular tachyarrythmias |
| WO2017214949A1 (zh) * | 2016-06-16 | 2017-12-21 | 毛侃琅 | 一种抑制 miRNA-29a 表达的慢病毒载体的构建及其应用 |
| WO2017219170A1 (zh) * | 2016-06-19 | 2017-12-28 | 毛侃琅 | 特异抑制人 miRNA-29a 和 miR-424 表达的慢病毒载体的构建及其应用 |
| WO2017219169A1 (zh) * | 2016-06-19 | 2017-12-28 | 毛侃琅 | 一种抑制 miRNA-29a 和 miR-185 表达的慢病毒载体及其应用 |
| EP3515459A4 (en) | 2016-09-20 | 2020-08-05 | Cedars-Sinai Medical Center | CELLS DERIVED FROM CARDIOSPHERES AND THEIR EXTRACELLULAR VESICLES TO DELAY OR REVERSE AGING AND AGE-RELATED DISORDERS |
| US11759482B2 (en) | 2017-04-19 | 2023-09-19 | Cedars-Sinai Medical Center | Methods and compositions for treating skeletal muscular dystrophy |
| US11660355B2 (en) | 2017-12-20 | 2023-05-30 | Cedars-Sinai Medical Center | Engineered extracellular vesicles for enhanced tissue delivery |
| EP3749344A4 (en) | 2018-02-05 | 2022-01-26 | Cedars-Sinai Medical Center | METHODS OF THERAPEUTIC USE OF EXOSOMES AND Y-RNAS |
| CN109762883B (zh) * | 2019-01-31 | 2020-01-21 | 温州医科大学 | 血浆/血清外泌体hsa-miRNA-29-3p作为青光眼诊断标志物中的应用 |
| CN110511930B (zh) * | 2019-06-11 | 2023-01-10 | 河北医科大学 | Sal-miR-58及其在抑制血管炎性反应和动脉瘤形成中的用途 |
| CN117979975A (zh) * | 2021-05-07 | 2024-05-03 | 加利福尼亚大学董事会 | 用于预防和治疗动脉瘤、高血压、ards和其他与内皮功能障碍相关联的疾病的mirna抑制剂 |
| US20250304956A1 (en) * | 2021-08-06 | 2025-10-02 | Leadermed Champion Limited | miRNA-BASED COMPOSITIONS AND METHODS OF USE THEREOF |
| CN114432453B (zh) * | 2022-02-25 | 2022-10-14 | 上海大学 | 敲低或抑制clec4d的试剂在制备心肌缺血再灌注损伤药物中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008042231A2 (en) | 2006-09-29 | 2008-04-10 | Children's Medical Center Corporation | Compositions and methods for evaluating and treating heart failure |
| ES2621161T3 (es) | 2007-07-31 | 2017-07-03 | The Board Of Regents Of The University Of Texas System | Familia de micro-ARN que modula la fibrosis y usos de la misma |
| CL2008003699A1 (es) * | 2007-12-13 | 2009-10-09 | Takeda Pharmaceuticals Co | Nanopartícula que comprende pioglitazona y un polímero biocompatible, preparación farmacéutica que la contiene; stent (endoprótesis vascular) que la porta; y su uso en la profilaxis o tratamiento de enfermedades arterioescleróticas. |
| CA2716343A1 (en) * | 2008-02-21 | 2009-08-27 | The Board Of Regents Of The University Of Texas System | Micro-rnas that modulate smooth muscle proliferation and differentiation and uses thereof |
-
2010
- 2010-04-01 EP EP10003675A patent/EP2371370A1/en not_active Withdrawn
-
2011
- 2011-04-01 JP JP2013501865A patent/JP6224455B2/ja active Active
- 2011-04-01 AU AU2011234453A patent/AU2011234453B2/en active Active
- 2011-04-01 WO PCT/EP2011/055122 patent/WO2011121120A1/en not_active Ceased
- 2011-04-01 EP EP11711597.2A patent/EP2552454B1/en active Active
- 2011-04-01 RU RU2012146518/15A patent/RU2012146518A/ru not_active Application Discontinuation
- 2011-04-01 CN CN2011800172888A patent/CN102939090A/zh active Pending
- 2011-04-01 CA CA2795164A patent/CA2795164C/en active Active
- 2011-04-01 US US13/637,924 patent/US9062307B2/en active Active
- 2011-04-01 ES ES11711597.2T patent/ES2690198T3/es active Active
-
2016
- 2016-03-24 JP JP2016060073A patent/JP2016193888A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US9062307B2 (en) | 2015-06-23 |
| CN102939090A (zh) | 2013-02-20 |
| EP2552454A1 (en) | 2013-02-06 |
| US20130116303A1 (en) | 2013-05-09 |
| ES2690198T3 (es) | 2018-11-19 |
| CA2795164A1 (en) | 2011-10-06 |
| JP6224455B2 (ja) | 2017-11-01 |
| EP2371370A1 (en) | 2011-10-05 |
| JP2016193888A (ja) | 2016-11-17 |
| CA2795164C (en) | 2019-06-18 |
| EP2552454B1 (en) | 2018-07-11 |
| AU2011234453A1 (en) | 2012-10-18 |
| WO2011121120A1 (en) | 2011-10-06 |
| JP2013523696A (ja) | 2013-06-17 |
| AU2011234453B2 (en) | 2015-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012146518A (ru) | Антагонисты экспрессии мкрнк-29 и их применение в профилактике и лечении аневризмы аорты | |
| JP2013523696A5 (enExample) | ||
| Suh et al. | Peptide-mediated intracellular delivery of miRNA-29b for osteogenic stem cell differentiation | |
| Chai et al. | Serum response factor is a critical requirement for VEGF signaling in endothelial cells and VEGF‐induced angiogenesis | |
| DK2217704T3 (en) | Method to promote angionesis, vascularization or vascular repair or to inhibit tumor angionesis | |
| Escudero-Paunetto et al. | SR proteins SRp20 and 9G8 contribute to efficient export of herpes simplex virus 1 mRNAs | |
| CA2977624A1 (en) | Pharmaceutical composition for treating cancer comprising microrna as active ingredient | |
| Zhang et al. | Silence of lncRNA XIST represses myocardial cell apoptosis in rats with acute myocardial infarction through regulating miR-449 | |
| WO2022271818A1 (en) | Antisense compounds and methods for targeting cug repeats | |
| Du et al. | Role of miR-199b-5p in regulating angiogenesis in mouse myocardial microvascular endothelial cells through HSF1/VEGF pathway | |
| Li et al. | MicroRNA‐129‐1‐3p regulates cyclic stretch–induced endothelial progenitor cell differentiation by targeting Runx2 | |
| Dorn | MicroRNAs: redefining mechanisms in cardiac disease | |
| Hassan et al. | Molecular mechanisms of cardiovascular benefits of exercise: Running for cover from heart disease | |
| EP4431117A1 (en) | Composition for diagnosis, prevention, or treatment of vascular smooth muscle cell proliferative disease, using mirna inhibitor | |
| JP5789927B2 (ja) | 放射線照射コラーゲン様ペプチドを用いた核酸導入法 | |
| EP2253705A1 (en) | Use of inhibitors of Zdhhc2 activity for modulation of adipogenesis | |
| Katoku-Kikyo et al. | Circadian timing-dependent myoblast differentiation and muscle regeneration | |
| Bardell | microRNA: target interactions in tendinopathy | |
| Von Kleeck | Mechanisms Of Early Arterial Stiffening And Reduced Smooth Muscle Contractility In The Premature Aging Disease Hutchinson-Gilford Progeria Syndrome | |
| Jouy | Regulation of cardiac fibroblast extracellular matrix synthesis by cell mechanics and polarity | |
| KR20150078074A (ko) | microRNA-365 활성화제를 포함하는 혈관평활근세포 증식 또는 이동 억제용 약학적 조성물 | |
| JP2013001675A (ja) | 血管新生制御剤およびその利用 | |
| EP4658679A1 (en) | Oligonucleotide encoding a tissue inhibitor of metalloproteases protein for medical use in mammals | |
| Ding et al. | Role of MicroRNAs in cardiac hypertrophy and postinfarction remodeling | |
| Yu et al. | MicroRNA as predictive and informative diagnostic tools and promising drug targets to monitor chronic cardiac disorders and to manage the patients and persons-at-risks |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20150922 |